{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:22Z","timestamp":1786979962345,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00296-020-04545-0","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T08:02:52Z","timestamp":1583827372000},"page":"719-726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8026-7773","authenticated-orcid":false,"given":"Alejandro","family":"Robles-Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-878X","authenticated-orcid":false,"given":"Jordi","family":"Dorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5410-5807","authenticated-orcid":false,"given":"Ivan","family":"Castellv\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2358-6767","authenticated-orcid":false,"given":"Joan Miquel","family":"Nolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1852-1723","authenticated-orcid":false,"given":"Maria","family":"Molina-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1614-8064","authenticated-orcid":false,"given":"Javier","family":"Narv\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"key":"4545_CR1","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/acr.21895","volume":"65","author":"I Marie","year":"2013","unstructured":"Marie I, Josse S, Hatron PY et al (2013) Interstitial lung disease in anti-Jo-1 patients with antisynthetase s\u00edndrome. Arthritis Care Res 65:800\u2013808. https:\/\/doi.org\/10.1002\/acr.21895","journal-title":"Arthritis Care Res"},{"key":"4545_CR2","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","volume":"51","author":"M Elhai","year":"2012","unstructured":"Elhai M, Meune C, Avouac J, Kahan A, Allanore Y (2012) Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and metaanalysis of cohort studies. Rheumatology (Oxford) 51:1017\u20131026. https:\/\/doi.org\/10.1093\/rheumatology\/ker269","journal-title":"Rheumatology (Oxford)"},{"key":"4545_CR3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/art.27405","volume":"62","author":"T Bongartz","year":"2010","unstructured":"Bongartz T, Nannini C, Medina-Velasquez YF et al (2010) Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 62:1583\u20131591. https:\/\/doi.org\/10.1002\/art.27405","journal-title":"Arthritis Rheum"},{"key":"4545_CR4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1378\/chest.09-0444","volume":"136","author":"E Kim","year":"2009","unstructured":"Kim E, Collard H, King TE Jr (2009) Rheumatoid arthritis-associated interstitial lung disease, the relevance of histopathologic and radiographic pattern. Chest 136:1397\u20131405. https:\/\/doi.org\/10.1378\/chest.09-0444","journal-title":"Chest"},{"key":"4545_CR5","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1517\/13543784.16.3.393","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655\u20132666. https:\/\/doi.org\/10.1517\/13543784.16.3.393","journal-title":"N Engl J Med"},{"key":"4545_CR6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double-blind, parallel group trial. Lancet Respir Med 4:708\u2013719. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"4545_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1759720X15612250","volume":"7","author":"K Iqbal","year":"2015","unstructured":"Iqbal K, Kelly C (2015) Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskel Dis 7:247\u2013267. https:\/\/doi.org\/10.1177\/1759720X15612250","journal-title":"Ther Adv Musculoskel Dis"},{"key":"4545_CR8","doi-asserted-by":"publisher","first-page":"R168","DOI":"10.1186\/ar4352","volume":"15","author":"A Francois","year":"2013","unstructured":"Francois A, Chatelus E, Wachsmann D et al (2013) B lymphocites and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther 15:R168. https:\/\/doi.org\/10.1186\/ar4352","journal-title":"Arthritis Res Ther"},{"key":"4545_CR9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/art.21758","volume":"54","author":"S Atkins","year":"2006","unstructured":"Atkins S, Turesson C, Myers J et al (2006) Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 54:635\u2013641. https:\/\/doi.org\/10.1002\/art.21758","journal-title":"Arthritis Rheum"},{"key":"4545_CR10","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","volume":"54","author":"H Andersson","year":"2015","unstructured":"Andersson H, Sem M, Lund MB et al (2015) Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology 54:1420\u20131428. https:\/\/doi.org\/10.1093\/rheumatology\/kev004","journal-title":"Rheumatology"},{"key":"4545_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.10.003","author":"D Daoussis","year":"2016","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G et al (2016) A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.10.003(Epub ahead of print)","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 100","key":"4545_CR12","first-page":"181","volume":"34","author":"G Lepri","year":"2016","unstructured":"Lepri G, Avouac J, Air\u00f2 P et al (2016) Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol 34(Suppl 100):181\u2013185","journal-title":"Clin Exp Rheumatol"},{"key":"4545_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.reuma.2013.09.003","volume":"10","author":"P Pe\u00f1acoba","year":"2014","unstructured":"Pe\u00f1acoba P, Corica ME, Mayos M et al (2014) Rituximab in the treatment of shrinking lung syndrome in systemic lupus erythematosus. Reumatol Clin 10:325\u2013327. https:\/\/doi.org\/10.1016\/j.reuma.2013.09.003","journal-title":"Reumatol Clin"},{"key":"4545_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1590\/s1679-45082014ao2706","volume":"12","author":"RI Lacerda","year":"2014","unstructured":"Lacerda RI, Scheinberg MA, Formiga MY et al (2014) Use of rituximab as a treatment for systemic lupus erythematosus: retrospective review. Einstein 12:36\u201341. https:\/\/doi.org\/10.1590\/s1679-45082014ao2706","journal-title":"Einstein"},{"key":"4545_CR15","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/rheumatology\/kew195","volume":"55","author":"C Sharp","year":"2016","unstructured":"Sharp C, McCabe M, Dodds N et al (2016) Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology 55:1318\u20131324. https:\/\/doi.org\/10.1093\/rheumatology\/kew195","journal-title":"Rheumatology"},{"key":"4545_CR16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","volume":"14","author":"D Giuggioli","year":"2015","unstructured":"Giuggioli D, Lumetti F, Colaci M et al (2015) Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev 14:1072\u20131078. https:\/\/doi.org\/10.1016\/j.autrev.2015.07.008","journal-title":"Autoimmun Rev"},{"key":"4545_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.autrev.2016.07.021","volume":"15","author":"L Duron","year":"2016","unstructured":"Duron L, Cohen-Aubart F, Diot E et al (2016) Shrinking lung syndrome associated with systemic lupus erythematosus: a multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. Autoimmun Rev 15:994\u20131000. https:\/\/doi.org\/10.1016\/j.autrev.2016.07.021","journal-title":"Autoimmun Rev"},{"key":"4545_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/resp.12214","volume":"19","author":"GJ Keir","year":"2014","unstructured":"Keir GJ, Maher TM, Ming D et al (2014) Rituximab in severe, tratment-refractory interstitial lung disease. Respirology 19:353\u2013359. https:\/\/doi.org\/10.1111\/resp.12214","journal-title":"Respirology"},{"issue":"3","key":"4545_CR19","first-page":"215","volume":"32","author":"DB Fitzgerald","year":"2015","unstructured":"Fitzgerald DB, Moloney F, Twomey M et al (2015) Efficacy and safety of rituximab in connective tissue disease related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 32(3):215\u2013221","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"6","key":"4545_CR20","first-page":"1077","volume":"34","author":"MH Chen","year":"2016","unstructured":"Chen MH, Chen CK, Chou HP et al (2016) Rituximab therapy in primary Sj\u00f6gren\u2019s syndrome with interstitial lung disease: a retrospective cohort study. Clin Exp Rheumatol 34(6):1077\u20131084","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"4545_CR21","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s10067-019-04557-7","volume":"38","author":"AC Duarte","year":"2019","unstructured":"Duarte AC, Cordeiro A, Fernandes BM et al (2019) Rituximab in connective tissue disease-associated interstitial lung disease. Clin Rheumatol 38(7):2001\u20132009. https:\/\/doi.org\/10.1007\/s10067-019-04557-7","journal-title":"Clin Rheumatol"},{"key":"4545_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00408-015-9767-x","volume":"193","author":"D Bennett","year":"2015","unstructured":"Bennett D, Fossi A, Bargagli E et al (2015) Mortality on the waiting list for lung transplantation in patients with idiopathic pulmonary fibrosis: a single-centre experience. Lung 193:677\u2013681. https:\/\/doi.org\/10.1007\/s00408-015-9767-x","journal-title":"Lung"},{"key":"4545_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/0366-6999.172547","volume":"129","author":"WX He","year":"2016","unstructured":"He WX, Tang UL, Xia Y et al (2016) Outcomes of Chinese patients with end-stage pulmonary disease while awaiting lung transplantation: a single-center study. Chin Med J 129:3\u20137. https:\/\/doi.org\/10.4103\/0366-6999.172547","journal-title":"Chin Med J"},{"key":"4545_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.transproceed.2011.12.059","volume":"44","author":"HC Paik","year":"2012","unstructured":"Paik HC, Haam SJ, Lee DY et al (2012) The fate of patients on the waiting list for lung transplantation in Korea. Transplant Proc 44:865\u2013869. https:\/\/doi.org\/10.1016\/j.transproceed.2011.12.059","journal-title":"Transplant Proc"},{"key":"4545_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.resinv.2017.03.002","volume":"55","author":"H Higo","year":"2017","unstructured":"Higo H, Kurosaki T, Ichihara E et al (2017) Clinical charactersitics of Japanese candidates for lung transplant for interstitial lung disease and risk factors for early death while on the waiting list. Respir Investig 55:264\u2013269. https:\/\/doi.org\/10.1016\/j.resinv.2017.03.002","journal-title":"Respir Investig"},{"key":"4545_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","author":"American Thoracic Society, European Respiratory Society","year":"2002","unstructured":"American Thoracic Society, European Respiratory Society (2002) American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by The ERS Executive Committee, June 2001. Am J Respir Crit Car Med 165:277\u2013304. https:\/\/doi.org\/10.1164\/ajrccm.165.2.ats01","journal-title":"Am J Respir Crit Car Med"},{"key":"4545_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.arbres.2011.03.007","volume":"47","author":"A Roman","year":"2011","unstructured":"Roman A, Borro JM, Ussetti P et al (2011) Selecci\u00f3n de pacientes candidatos a trasplante pulmonar. Arch Bronconeumol 47:303\u2013309. https:\/\/doi.org\/10.1016\/j.arbres.2011.03.007","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"4545_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","volume":"18","author":"P Saunders","year":"2017","unstructured":"Saunders P, Tsipouri V, Keir GJ et al (2017) Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomized controlled trial. Trials 18(1):275. https:\/\/doi.org\/10.1186\/s13063-017-2016-2","journal-title":"Trials"},{"issue":"11","key":"4545_CR29","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/1346-8138.15079","volume":"46","author":"S Ebata","year":"2019","unstructured":"Ebata S, Yoshizaki A, Fukasawa T et al (2019) Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. J Dermatol 46(11):1006\u20131013. https:\/\/doi.org\/10.1111\/1346-8138.15079","journal-title":"J Dermatol"},{"key":"4545_CR30","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3899\/jrheum.130764","volume":"40","author":"M Eberlein","year":"2013","unstructured":"Eberlein M (2013) Shrinking lung syndrome as a manifestation of pleuritis: are surface forces and surfactant the pathophysiological link ? J Rheumatol 40:1926. https:\/\/doi.org\/10.3899\/jrheum.130764","journal-title":"J Rheumatol"},{"key":"4545_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/qjmed\/hcq095","volume":"104","author":"LA P\u00e9rez de Llano","year":"2011","unstructured":"P\u00e9rez de Llano LA, Castro-A\u00f1on O, L\u00f3pez MJ et al (2011) Shrinking lung syndrome caused by lupus myopathy. Q J Med 104:259\u2013262. https:\/\/doi.org\/10.1093\/qjmed\/hcq095","journal-title":"Q J Med"},{"key":"4545_CR32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/art.1780280709","volume":"28","author":"S Jacobelli","year":"1985","unstructured":"Jacobelli S, Moreno R, Massardo L et al (1985) Inspiratory muscle dysfunction and unexplained dyspnea in systemic lupus erythematosus. Arthritis Rheum 28:781\u2013788. https:\/\/doi.org\/10.1002\/art.1780280709","journal-title":"Arthritis Rheum"},{"key":"4545_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/thorax.56.4.329","volume":"56","author":"P Hawkins","year":"2001","unstructured":"Hawkins P, Davison AG, Dasgupta B et al (2001) Diaphragm strenght in acute systemic lupus erythematosus in a patient with paradoxical abdominal motion and reduced lung volumes. Thorax 56:329\u2013330. https:\/\/doi.org\/10.1136\/thorax.56.4.329","journal-title":"Thorax"},{"key":"4545_CR34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1378\/chest.93.2.352","volume":"93","author":"PG Wilcox","year":"1988","unstructured":"Wilcox PG, Stein HB, Clarke SD et al (1988) Phrenic nerve function in patients with diaphragmatic weakness and systemic lupus erythematosus. Chest 93:352\u2013358. https:\/\/doi.org\/10.1378\/chest.93.2.352","journal-title":"Chest"},{"key":"4545_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3899\/jrheum.121048","volume":"40","author":"LA Henderson","year":"2013","unstructured":"Henderson LA, Loring SH, Gill RR et al (2013) Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies. J Rheumatol 40:273\u2013281. https:\/\/doi.org\/10.3899\/jrheum.121048","journal-title":"J Rheumatol"},{"key":"4545_CR36","doi-asserted-by":"publisher","first-page":"33(e4626)","DOI":"10.1097\/MD.0000000000004626","volume":"95","author":"H Borrell","year":"2016","unstructured":"Borrell H, Narv\u00e1ez J, Alegre JJ et al (2016) Shrinking lung syndrome in systemic lupus erythematosus. Medicine 95:33(e4626). https:\/\/doi.org\/10.1097\/MD.0000000000004626","journal-title":"Medicine"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04545-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-020-04545-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04545-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T19:25:56Z","timestamp":1615317956000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-020-04545-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4545"],"URL":"https:\/\/doi.org\/10.1007\/s00296-020-04545-0","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,10]]},"assertion":[{"value":"26 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors state they have no conflict of interest and no relationship with pharmaceutical agencies promoting rituximab or other biologic treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference for Harmonization. The manuscript has been approved for its publication by the Clinical Research Ethics Committee of Bellvitge University Hospital (reference number PR406\/17).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}